Clinical Trials · NCT06632457
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
- Phase
- Phase 3
- Recruitment status
- Recruiting
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 1,590
- Start date
- Nov 2024
- Locations
- 444 sites, 36 countries
- Primary endpoint
- Time to first occurrence of any component of the composite clinical endpoint (at EoS) consisting of: all-cause mortality, liver transplant, hepatic decompensation events, worsening of MELD score to ≥15 and progression to CSPH